类模拟剂激活蛋白质组:帕金森病治疗的新视角
Karolina Trepczyk1, Safak Er2, Irena Hlushchuk2
1Department of Biomedical Chemistry, Faculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308 Gdańsk, Poland.
Journal of medicinal chemistry
|April 7, 2025
概括
新的类模拟剂有效地刺激蛋白质体,增强诸如α-synuclein和tau等有毒蛋白质的清除. 这种方法对治疗神经退行性疾病 (如帕金森氏症和阿尔茨海默氏症) 是有前途的.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 与年龄相关的神经退行性疾病涉及错误折叠的蛋白质的积累.
- 细胞蛋白质降解,主要是通过20S蛋白酶体,随着年龄的增长而下降.
- 刺激蛋白酶活性是神经退行性疾病的潜在治疗策略.
研究的目的:
- 开发和评估作为蛋白质酶激活剂的新型类模拟剂.
- 评估这些化合物在降解关键神经退行性疾病蛋白质方面的有效性.
- 为了确定类仿制药的安全性和细胞透.
主要方法:
- 生物化学测试和细胞培养实验被用来测试蛋白质酶刺激.
- 评估了类药物在人体血中的稳定性和细胞膜透.
- 测量了α-synuclein和tau蛋白质的降解.
- 对HEK293T和原发性海马细胞进行了细胞毒性测试.
- 用小鼠胚胎细胞模型来评估化α-synuclein聚合物的减少.
主要成果:
- 类药物在体外和细胞培养中有效刺激了20S蛋白酶活性.
- 这些化合物在人体血和细胞膜透性中表现出稳定性.
- 观察到α-synuclein和tau的增强降解.
- 在测试的细胞系中没有检测到细胞毒性.
- 在细胞模型中实现了化α-synuclein聚合物的显著减少.
结论:
- 新型类模拟剂是具有治疗潜力的强效蛋白酶激活剂.
- 这些化合物可以增强与帕金森氏症和阿尔茨海默氏症相关的蛋白质的清除.
- 开发的类仿制药在细胞模型中是安全和有效的,需要进一步研究.
相关概念视频
01:24Parkinson's Disease: Treatment
161
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
161
01:15Parkinson's Disease: Overview
342
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
342
01:13The Proteasome
781
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
781
01:22Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
01:17The Proteasome Structure
650
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
650